An oral formulation was abandoned by Johnson and Johnson due to poor injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan.
An oral formulation was abandoned by Johnson and Johnson due to poor injectable version and with Shionogi Pharmaceuticals in Japan. This was in partnership with Green Cross Pharmaceuticals in South Korea.